Production of various combinations of bispecific variable domain of heavy chain of heavy chainonly antibody (VHH) constructs to evaluate their therapeutic potential usually requires several gene-engineering steps. Here, we present an alternative method of creating bispecific VHH constructs in vivo through protein trans-splicing (PTS) reaction; this method may reduce the number of gene manipulation steps required. As a proof-of-concept, we constructed a bispecific antibody (bsAb) containing an anti-epidermal growth factor receptor VHH and anti-green fluorescent protein VHH, and we evaluated and confirmed its bispecificity. We also tested antibody labeling by fluorescent protein tagging using the PTS reaction. Compared with the conventional gene construction method, bsAb construction via PTS is a promising alternative approach for generating multiple bsAb combinations.
Introduction
A bispecific antibody (bsAb) is an engineered antibody that can simultaneously recognize two different antigens. bsAbs have great potential as next-generation biological therapeutics for cancer therapy because they can bridge cancer antigens and immune cell antigens, thereby enhancing the efficiency of immune cell recruitment to cancer cells (May et al., 2012; Weiner, 2015) . Several bsAb formats have been proposed. One of the simplest formats consists of two minimal antigen-binding domains, while a conventional bsAb has an IgG-type structure (Byrne et al., 2013) . For example, bispecific T-cell engagers (BiTEs), which have been developed for cancer drugs, consist of two different single-chain variable fragments (scFvs) linked in tandem by a polypeptide linker (Baeuerle and Reinhardt, 2009; Frankel and Baeuerle, 2013) . A camel heavy chain antibody variable region (VHH) can also be used to generate a bispecific VHH construct (Els Conrath et al., 2001) .
To develop a highly effective bsAb, it is necessary to evaluate several combinations of different antibody clones. Even bsAbs that recognize the same antigens may have different potencies depending on the combination of the antibody clones (Bluemel et al., 2010) . Furthermore, the domain order of Fv chains also affects bsAb activity (Asano et al., 2013) . These observations suggest that a precise evaluation of several bsAb combinations is necessary to develop highly efficient bsAbs. One of the limitations of this evaluation step is the construction of expression vectors. For example, to test the combination of antibodies with any two (n and m) specificities, the number of combinations of bsAbs is 2 × (n × m), and thus 2 × (n × m) vector constructs would be required (the multiplication by two reflects two possible domain orders, i.e. N-and C-termini in each VHH clone.). Although several high-throughput methods have been reported for the generation of expression vectors with cloned genes, expression vector construction remains a time-consuming step .
To overcome this limitation, we developed an alternative bsAb construction method using a split-intein system. Intein is an enzyme that catalyzes the splicing reaction of its N-and C-terminal flanking polypeptides (Anraku et al., 2005) . This enzyme is now employed in several biotechnology applications, including segmental isotope labeling and protein chemical modifications; the latter is achieved via the formation of a thioester at the C-terminus of the target protein, in a process called expressed protein ligation (EPL) (Muralidharan and Muir, 2006; Vila-Perello and Muir, 2010; Topilina and Mills, 2014) . Naturally occurring split inteins mediate the splicing reaction in trans (Aranko et al., 2014) . The reaction, called protein trans-splicing (PTS), can ligate not only the original flanking peptides of the intein but also exogenous protein fragments. Thus, using split inteins, the ligation reaction can be performed in a highly specific manner. It should be noted that EPL and PTS use different reaction mechanisms: EPL uses native chemical ligation and PTS uses intein-based enzyme catalysis. Iwai's group at the University of Helsinki developed an in vivo PTS system in Escherichia coli using a naturally split DnaE intein from Nostoc punctiforme, which has been reported to mediate a rapid, efficient trans-splicing reaction (Iwai et al., 2006) . The in vivo trans-splicing system consists of two independent expression vectors: one for the N-terminal split intein and the other for the C-terminal split intein. These two vectors have different origins of replication (ori), antibiotic resistance genes and promoters, and thus can be used to compatibly co-transform one host cell, with the expression of fusion genes induced by different inducers (Muona et al., 2010) .
Here, we applied this PTS system to create a bsAb. Each camelid VHH antibody fragment was fused with N-and C-termini of the split intein, N-terminal fragment of a split intein (IntN) and C-terminal fragment of a split intein (IntC), respectively. Using PTS, various types of antibodies can be combined to generate bsAbs without the necessity for individual vector construction. As a result, 2 × (n × m) combinations of bsAbs can be created using 2n + 2m vector constructs, where n and m represent the numbers of antibody clones.
Results and discussion

In vivo PTS reaction for bsAb production
We generated bsAbs through split intein-mediated PTS and evaluated the resultant products. Figure 1 shows the scheme of in vivo PTS reaction. Using this method, two separate VHH antibody fragments can be connected in a traceless manner (Fig. 1) . Two split inteins form an active complex in vivo, and the intact intein joins the two flanking polypeptides. C-terminus of the N-terminal side of VHH and N-terminus of the C-terminal side of VHH are linked by a peptide bond. We chose an anti-epidermal growth factor receptor (EGFR) VHH (Ia1) (Roovers et al., 2006) and an anti-green fluorescent protein (GFP) VHH (cAbGFP4) (Rothbauer et al., 2006) to generate a bsAb as a proof-of-concept of the in vivo trans-splicing method. Because EGFR, an important target for cancer immunotherapy, is widely expressed on human cancer cells and GFP shows strong fluorescence, the resulting bsAb could be easily evaluated by measuring GFP fluorescence on cancer cell surface. For clarity, we refer to Ia1 as VHH EGFR (Anti-EGFR VHH Ia1) and cAbGFP4 as VHH GFP (Anti-GFP VHH cAbGFP4). VHH EGFR was fused at the N-terminus of IntN, termed VHH EGFR -IntN, and VHH GFP was fused at the C-terminus of IntC, termed IntC-VHH GFP (as shown in Fig. 1 ).
Construction of VHH EGFR and VHH GFP bsAb
E. coli cells transformed with two expression vectors encoding VHH fused with split-intein fragments were grown to OD 600 = 0.6 (Fig. 2a, Lane 1) , and the expression of IntC-VHH GFP was induced by the addition of L-arabinose. After 30 min of L-arabinose induction, the expression of IntC-VHH GFP was observed as a protein band with a molecular weight of 18.5 kDa (Fig. 2a, Lane 2) . Subsequently, isopropyl β-D-1 thiogalactopyranoside (IPTG) was added to induce the expression of VHH EGFR -IntN (molecular weight: 27.3 kDa). After 2.5 and 5 h of IPTG induction, the ligated product, VHH EGFR -VHH GFP (molecular weight: 29.9 kDa) was detected on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel (Fig. 2a , Lanes 3 and 4). The expression of VHH EGFR -IntN could not be followed by SDS-PAGE because almost all of the expressed VHH EGFR -IntN reacted with the pre-existing IntC-VHH GFP to immediately produce the final product, VHH EGFR -VHH GFP . We performed western blotting to verify the reaction products using anti-FLAG tag and anti-(His) 6 tag antibodies ( Fig. 2b and c) . A FLAG tag was fused with the C-terminus of IntC-VHH GFP , and the band appearing after L-arabinose induction (Fig. 2a , Lane 2) was accordingly detected with the anti-FLAG antibody (Fig. 2b , Lane 2). These observations suggested that this band was indeed IntC-VHH GFP . In addition to the IntC-VHH GFP band,~21 kDa degradation product was also detected by the anti-FLAG antibody in Lanes 3, 4, P and F (Fig. 2b) . After IPTG induction, the anti-FLAG antibody detected a higher molecular weight band (Fig. 2b , Lanes 3 and 4). Because the FLAG tag was located at the C-terminus of VHH GFP , the higher molecular weight band would be expected to be the ligation product, VHH EGFR -VHH GFP (i.e. the bsAb). A (His) 6 -tag was fused with the N-terminus of VHH EGFR -IntN, and anti-(His) 6 tag western blotting detection indicated the formation of VHH EGFR -VHH GFP (Fig. 2c , Lanes 3 and 4). Minor smaller molecular weight bands were detected besides the major VHH EGFR -VHH GFP bands (Fig. 2c , Lane 3 and 4). These bands correspond to VHH EGFR -IntN, as verified by independent expression of VHH EGFR -IntN ( Supplementary Fig. 1 , Fig. 1 Construction of bsAbs via in-cell PTS. Two separated camelid antibody fragments (VHHs) were fused into one bsAb molecule through a trans-splicing reaction. The VHH antibody fragment can be labeled with GFP in the same manner. Fig. 1 , Lanes 2 and 3) and VHH EGFR -IntN was not observed after Ni-NTA purification (Fig. 2c , Lane E). The anti-(His) 6 antibody also detected a degradation product (lower bands in Fig. 2c , Lanes 3 and 4).
Lanes 1-3). Unreacted VHH EGFR -IntN formed insoluble aggregates, as verified by SDS-PAGE (Supplementary
Following the in-cell trans-splicing reaction, the reaction product was purified from cell lysates using Ni-NTA column (Fig. 2 , Lanes P, F, W and E). A single band was observed in the elution fraction on SDS-PAGE gel (Fig. 2 , Lane E). Since (His) 6 tag was fused to the N-terminus of VHH EGFR , the detected band likely corresponded to VHH EGFR -VHH GFP bsAb, as it was also detected by the anti-FLAG and anti-(His) 6 tag antibodies ( Fig. 2b and c) . Moreover, bsAb was the only species with both a (His) 6 tag and a FLAG tag during this in vivo reaction (Fig. 2) . The final yield of VHH EGFR -VHH GFP was 1.91 mg/L culture. A low yield of PTS-generated proteins compared with that of genetically constructed proteins is a common issue of the PTS system (Shah et al., 2012) . This relatively low yield may be due to aggregate formation ( Supplementary Fig. 1 ). We determined the yield of genetically constructed VHH EGFR -VHH GFP to be 0.4 mg/L culture (Supplementary Information and Supplementary  Fig. 2) . One of the reasons for the lower yield of genetically constructed VHH EGFR -VHH GFP was the formation of inclusion bodies ( Supplementary Fig. 2 , Lane 2). Protein yield within a similar range (0.4-0.8 mg/mL) was previously reported for a genetically constructed VHH bispecific construct expressed in E. coli cells (Els Conrath et al., 2001) .
We then analyzed the molecular size of the ligation product, VHH EGFR -VHH GFP , by size-exclusion chromatography. A single dominant peak was apparent in the chromatogram (Fig. 3) . The peak appeared between 13.7 kDa (RNaseA) and 44.0 kDa (ovalbumin) molecular markers. Because the expected molecular weight of the VHH EGFR -VHH GFP monomer was 29.9 kDa, the single peak may correspond to the monomeric species; the single peak had a shoulder and this shoulder may reflect the impurity of the sample.
The binding affinity of VHH EGFR -VHH GFP toward EGFR and GFP was measured by surface plasmon resonance (SPR) experiments ( Fig. 4a and b) . A two-state binding model afforded a good fit of the data for the EGFR binding, perhaps illustrating an induced fit of binding loops of VHH EGFR during binding to EGFR, while 1:1 Langmuir binding model was best fitted for the data of VHH GFP binding toward GFP. The binding constants toward EGFR and GFP were determined to be 31.7 nM and 0.13 nM, respectively, and were on the same order of magnitude as the VHH EGFR -EGFR (15 nM) (Osaki et al., 2015) and VHH GFP -GFP (0.32 nM) binding constants (Saerens et al., 2005) .
Verification of VHH EGFR -VHH GFP bispecificity by flow cytometry analysis
The ability of VHH EGFR -VHH GFP to bridge EGFR and GFP was evaluated by flow cytometry using EGFR + A431 cells, an epidermoid carcinoma cell line overexpressing human EGFR. We observed GFP fluorescence only when the cells were incubated with both VHH EGFR -VHH GFP and GFP (Fig. 4c, left) . When the samples contained (1) only the cells, (2) only the cells with VHH EGFR -VHH GFP or (3) only the cells with GFP, autofluorescence, but not GFP fluorescence, was observed (Fig. 4c, left) . Similarly, increase of fluorescence was not detected when we submitted EGFR -CHO-K1 cells to the same procedure (Fig. 4c, right) . These results indicated that VHH EGFR -VHH GFP specifically recognized the EGFR molecule and was indeed able to act as a bridge between EGFR on the A431 cells and the GFP molecule.
GFP labeling of the antibody fragment
Combining two proteins by PTS ligation is not limited to antibody fragments, but can also be used for any functional proteins. Once an expression vector is created for bsAb production, the vector can be used for functionalization with other protein molecules. To test antibody functionalization, we evaluated labeling of VHH EGFR with GFP. GFP gene from Aequorea victoria was cloned into pSKBAD01 vector as an IntC fusion (see Materials and Methods), with the VHH EGFR -IntN expression vector identical to that used for bsAb production. PTS of VHH EGFR -GFP was performed in the same manner as for VHH EGFR -VHH GFP bsAb production. Figure 5a shows SDS-PAGE analysis and anti-(His) 6 tag western blotting results of protein co-expression and purification of the VHH EGFR -GFP product of in vivo PTS. Expression of IntC-GFP (31 kDa) was induced by L-arabinose (Fig. 5a , compare Lanes 1 and 2), and IPTG was used to induce the expression of VHH EGFR -IntN (27 kDa). Because VHH EGFR -IntN immediately reacts with a pre-existing IntC-GFP, no VHH EGFR -IntN band was detected after SDS-PAGE. However, a product band, VHH EGFR -GFP, was apparent (Fig. 5a , compare Lane 3 and Lane 4; 42.9 kDa). Absence of VHH EGFR -IntN was also confirmed by anti-(His) 6 tag western blotting (Fig. 5a , Lane 4). Purified VHH EGFR -GFP was obtained after one-step Ni-NTA column purification (Fig. 5a , Lane E). The yield was 7.12 mg/L culture. GFP fluorescence was detected in the purified protein sample, indicating that the GFP constituent of VHH EGFR -GFP was active (Fig. 5b) . SPR experiments revealed that VHH EGFR constituent of VHH EGFR -GFP possesses EGFR-binding activity, with K d of 9.21 nM, comparable with that of VHH EGFR (15 nM) (Fig. 4b) . Next, we used VHH EGFR -GFP to stain EGFR + A431 cancer cells or EGFR -CHO-K1 cells (as control), and imaged the cells using fluorescence microscopy (Fig. 6 ). A431 cell surface was strongly marked by GFP fluorescence, while the CHO-K1 cell surface was only weakly stained. We also performed flow cytometry analysis of VHH EGFR -GFP/cell line binding ( Supplementary Fig. 3 ). Similarly to fluorescent microscopy data, results of the flow cytometry analysis also indicated specific binding of VHH EGFR -GFP to EGFR + cells. In addition, the data ruled out the possibility of A431 cell autofluorescence in the fluorescent microscopy image. Collectively, this suggested that antibody functionalization is indeed possible through alteration of the split-intein fusion protein.
In conclusion, our results demonstrate that PTS in vivo can constitute an alternative approach for the construction of functional bsAbs. We here successfully constructed a VHH EGFR -VHH GFP bsAb by engineering two antibody fragments as a split-intein fusion. This approach could also be used for the construction of biparatopic antibodies that recognize different portions of the same antigen. We are now working on other combinations of antibody fragments, including scFv fragments. By replacing one domain of a bsAb antibody with any functional protein, e.g. toxin or cytokine, the resulting products become immunotoxins and immunocytokines (Kiefer and Neri, 2016) . Thus, once the putative antibody clone is created, bsAbs and functional antibodies can immediately be generated by co-transformation of the counterpart split-intein fusion vector.
Because we have only tested one bispecific VHH construct here, the generality of this method for other VHH clones needs to be examined in future studies. It should also be mentioned that although our method may reduce the number of bsAb construction steps it does not reduce the protein purification and evaluation steps after PTS, the most time-consuming steps. The application of our method is currently limited to the construction of bsAbs in the cytosol; hence, these proteins are expressed as intrabodies. A ligation reaction in the periplasm, fusing a signal peptide with the appropriate protein terminus, may overcome this limitation after further optimization of the expression conditions. In addition to the combination of antibody clones, the domain order and linker sequence are critical for antibody activity. It has been shown that the location of VHH (Nor C-terminus) in a bispecific construct affects binding affinity toward an antigen (Els Conrath et al., 2001) . Considering the domain order, 2 × (n × m) expression vectors will have to be prepared for the N-terminal and C-terminal version of each antibody clone. The linker introduces flexibility between the two linked domains and it may be critical for bsAb activity. Our current design results in GSCFNGT linker after the PTS reaction, with a free cysteine at the splicing site, a required residue for the PTS reaction; this free cysteine may induce the formation of non-specific dimer. Thus, the linker sequence and length may need to be redesigned to further improve the activity of the antibody. The domain order and linker aspects will be explored in our future studies, paving the way for next-generation drugs.
Materials and methods
Vector construction
Sequences encoding camelid VHHs for EGFR (Ia1; VHH EGFR ) and GFP (cAbGFP4; VHH GFP ) were used to construct the split-intein fusion vectors. Syntheses of these VHH genes have been reported previously (Hattori et al., 2010; Tawa et al., 2011; Tawa et al., 2013) . We used pSKDuet01 and pSKBAD2 vectors for split-intein fusion constructions. These two vectors were a gift from Hideo Iwai (Addgene plasmids #12172 and #15335) (Muona et al., 2010) . NcoI and BamHI restriction sites of the pSKDuet01 vector were used for IntN fusion, and KpnI and HindIII sites of the pSKBAD2 vector were used for IntC fusion. Expression vector encoding a genetically fused bsAb (VHH EGFR -VHH GFP ) was constructed by subcloning VHH GFP gene from a previously reported vector, pRA 4F2 VHH-LH-VHH GFP (Tawa et al., 2011) , into BamHI-SacII sites of pRA VHH EGFR -LH-4F2 VHH (Tawa et al., 2013) .
Protein generation via trans-splicing reaction
Chemically competent E. coli BL21(DE3) cells were simultaneously transformed with pSKDuet01-VHH EGFR and pSKBAD2-VHH GFP (or pSKBAD2-GFP) vectors. The cells were cultured overnight at 37°C in 20 mL of LB medium with 10 μg/mL of ampicillin and 30 μg/mL of kanamycin, and used to inoculate 500 mL of LB medium in a 2-L baffled flask. As the cultures reached OD 600 = 0.6, L-arabinose solution was added to a final concentration of 0.4% (w/v) to induce the expression of the first precursor (IntC fusion), and the culture temperature was decreased to 25°C. After 30 min, the second precursor (IntN fusion) was induced by the addition of IPTG to a final concentration of 1 mM. Cells were harvested 4 h after the second induction. Cells were collected by centrifugation and resuspended in 20 mL of 50 mM Tris-HCl, pH 8.0. The supernatant of the sonicated suspension was loaded onto an Ni-NTA column (Hitrap His FF, GE Healthcare, USA). The elution fraction was concentrated using an Amicon Ultra Concentrator (MWCO 10 000; Millipore, USA). Genetically fused VHH EGFR -VHH GFP was expressed and purified as described previously (Hattori et al., 2010) .
Western blot analysis
We used the anti-FLAG monoclonal antibody M2 (1:10 000 dilution; Sigma, USA) and anti-(His) 6 -tag mAb-HRP-DirectT antibody (1:10 000 dilution; MBL Co. Ltd., Japan) in western blot experiments (Burnette, 1981) . A horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody (1:10 000 dilution; Sigma) was used to detect the M2 antibodies. HRP activity was visualized using a colorimetric substrate (TMB Membrane Peroxidase Substrate; KPL, USA).
Analytical size-exclusion chromatography
Purified proteins were analyzed using an analytical size-exclusion chromatography column (Superdex 200 Increase; GE Healthcare) in a buffer containing 50 mM Tris-HCl (pH 8.0) and 150 mM NaCl, with 3 mL/min flow rate, to evaluate their size distributions. Sample (100 μL;~10 μM) was loaded onto the column. The following protein size standards were used: RNaseA and ovalbumin from Gel Filtration Calibration Kit LMW (GE Healthcare).
Mammalian cell culture conditions
A431 and CHO-K1 cells were obtained from RIKEN BRC Cell Bank (Tsukuba, Ibaraki, Japan) and grown at 37°C in an atmosphere of 5% CO 2 in RPMI-1640 medium (Nacalai Tesque, Japan) supplemented with 10% fetal bovine serum, penicillin, streptomycin and amphotericin B.
Flow cytometry analysis
A431 and CHO-K1 cells [10 6 cells per sample in phosphatebuffered saline (PBS)] were incubated with 10 μM VHH EGFR -VHH GFP for 30 min. The cells were then washed three times with PBS containing 0.1% NaN 3 and incubated on ice with 10 μM GFP for 30 min. The cells were again washed three times with PBS containing 0.1% NaN 3 to remove unbound GFP molecules, and then filtered through a nylon mesh strainer. The cells were then analyzed by flow cytometry (BD Accuri C6; BD Biosciences, USA). Excitation laser set at 488 nm and detection filter at 530 nm were used to observe GFP fluorescence. The experiments were performed twice.
SPR analysis of VHH EGFR -VHH GFP and VHH EGFR -GFP
SPR experiments were performed to determine the binding constants of VHH EGFR domains of VHH EGFR -VHH GFP and VHH EGFR -GFP, and VHH GFP domain of VHH EGFR -VHH GFP at 25°C. Extra-cellular domain of EGFR (sEGFR) was expressed and purified as described previously (Makabe et al., 2008) . Biacore T200 and CM5 sensor chip (GE Healthcare) were used in these experiments. sEGFR was immobilized on the chip by amine coupling to 1920 resonance units (RU). Because the immobilized GFP did not show any binding activity, perhaps because of its denaturation on the chip, VHH EGFR -VHH GFP was immobilized on the chip to 2200 RU to observe GFP binding to VHH GFP of VHH EGFR -VHH GFP . A two-state binding model was used to fit the experimental data for sEGFR binding and a 1:1 Langmuir binding model was used for GFR binding, using BIAevaluation software (GE Healthcare) ( Fig. 4b and c, respectively).
Fluorescent spectroscopy
Fluorescent spectra of VHH EGFR -GFP were acquired with FP-8200 fluorescent spectrometer (Jasco, Japan) at room temperature. Emission spectrum for 1.0 μM sample (i.e. protein in PBS buffer) in 1-cm cuvette was measured at an excitation wavelength of 450 nm (5 nm bandwidth). Water background-subtracted spectrum is shown.
Fluorescent microscopy
Fluorescent microscopy images of A431 and CHO-K1 cells were obtained using a confocal laser-scanning microscope (FluoviewFV10i; Olympus, Japan) with a 60 × lens. Cells were cultured in a poly-lysine treated glass bottom dish and stained with 10 μM VHH EGFR -GFP in PBS. After washing two times with PBS, the dish was placed in the microscope chamber. GFP fluorescence was observed using a 473-nm excitation laser and emission filter of 490-540 nm.
Supplementary data
Supplementary data are available at PEDS online.
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